EP
Eversept Partners’s Apellis Pharmaceuticals APLS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-122,643
| Closed | -$4.67M | – | 58 |
|
|
2023
Q3 | $4.67M | Buy |
122,643
+66,194
| +117% | +$2.52M | 0.39% | 38 |
|
|
2023
Q2 | $5.14M | Buy |
+56,449
| New | +$5.14M | 0.43% | 38 |
|
|
2023
Q1 | – | Sell |
-154,796
| Closed | -$8M | – | 60 |
|
|
2022
Q4 | $8M | Buy |
+154,796
| New | +$8M | 0.7% | 31 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 94 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 91 |
|
|
2021
Q2 | – | Sell |
-12,900
| Closed | -$554K | – | 71 |
|
|
2021
Q1 | $554K | Buy |
12,900
+9,084
| +238% | +$390K | 0.04% | 71 |
|
|
2020
Q4 | $218K | Sell |
3,816
-77,451
| -95% | -$4.43M | 0.03% | 57 |
|
|
2020
Q3 | $2.45M | Sell |
81,267
-339,665
| -81% | -$10.2M | 0.54% | 33 |
|
|
2020
Q2 | $13.7M | Sell |
420,932
-478,542
| -53% | -$15.6M | 1.89% | 16 |
|
|
2020
Q1 | $24.1M | Buy |
899,474
+589,065
| +190% | +$15.8M | 5.99% | 5 |
|
|
2019
Q4 | $9.5M | Buy |
310,409
+230,900
| +290% | +$7.07M | 1.68% | 16 |
|
|
2019
Q3 | $1.92M | Sell |
79,509
-37,800
| -32% | -$911K | 0.59% | 36 |
|
|
2019
Q2 | $2.97M | Buy |
117,309
+12,960
| +12% | +$328K | 0.83% | 27 |
|
|
2019
Q1 | $2.03M | Sell |
104,349
-2,531
| -2% | -$49.4K | 0.59% | 30 |
|
|
2018
Q4 | $1.41M | Buy |
106,880
+6,585
| +7% | +$86.9K | 0.76% | 25 |
|
|
2018
Q3 | $1.78M | Buy |
100,295
+1,900
| +2% | +$33.8K | 0.78% | 24 |
|
|
2018
Q2 | $2.16M | Buy |
+98,395
| New | +$2.16M | 0.99% | 22 |
|